1,041
Views
27
CrossRef citations to date
0
Altmetric
Original Research

Tumor lymphocyte immune response to preoperative radiotherapy in locally advanced rectal cancer: The LYMPHOREC study

, , , , , , , , , & , MD, PhD show all
Article: e1396402 | Received 31 Jul 2017, Accepted 19 Oct 2017, Published online: 27 Nov 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Kim Cao, Louisa Abbassi, Emanuela Romano & Youlia Kirova. (2021) Radiation therapy and immunotherapy in breast cancer treatment: preliminary data and perspectives. Expert Review of Anticancer Therapy 21:5, pages 501-510.
Read now

Articles from other publishers (25)

Seung Hyuck Jeon, Changhoon Song, Keun-Yong Eom, In Ah Kim & Jae-Sung Kim. (2023) Modulation of CD8+ T Cell Responses by Radiotherapy—Current Evidence and Rationale for Combination with Immune Checkpoint Inhibitors. International Journal of Molecular Sciences 24:23, pages 16691.
Crossref
Dorothée Sartorius, Moritz Leander Blume, Johannes Robert Fleischer, Michael Ghadimi, Lena-Christin Conradi & Tiago De Oliveira. (2023) Implications of Rectal Cancer Radiotherapy on the Immune Microenvironment: Allies and Foes to Therapy Resistance and Patients’ Outcome. Cancers 15:21, pages 5124.
Crossref
Ioannis M. Koukourakis, Kalliopi Platoni, Dina Tiniakos, Vassilis Kouloulias & Anna Zygogianni. (2023) Immune Response and Immune Checkpoint Molecules in Patients with Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy: A Review. Current Issues in Molecular Biology 45:5, pages 4495-4517.
Crossref
Chrysanthi Iliadi, Laurine Verset, Christelle Bouchart, Philippe Martinive, Dirk Van Gestel & Mohammad Krayem. (2023) The current understanding of the immune landscape relative to radiotherapy across tumor types. Frontiers in Immunology 14.
Crossref
Silvia Takanen, Marta Bottero, Paola Nisticò & Giuseppe Sanguineti. (2022) A Systematic Review on the Impact of Hypofractionated and Stereotactic Radiotherapy on Immune Cell Subpopulations in Cancer Patients. Cancers 14:21, pages 5190.
Crossref
Chia-Lin Chou, Tzu-Ju Chen, Wan-Shan Li, Sung-Wei Lee, Ching-Chieh Yang, Yu-Feng Tian, Cheng-Yi Lin, Hong-Lin He, Hung-Chang Wu, Yow-Ling Shiue, Chien-Feng Li & Yu-Hsuan Kuo. (2022) Upregulated Ubiquitin D is a Favorable Prognostic Indicator for Rectal Cancer Patients Undergoing Preoperative Concurrent Chemoradiotherapy. OncoTargets and Therapy Volume 15, pages 1171-1181.
Crossref
Icro Meattini, Lorenzo Livi, Nicla Lorito, Carlotta Becherini, Marina Bacci, Luca Visani, Alessandra Fozza, Liliana Belgioia, Mauro Loi, Monica Mangoni, Matteo Lambertini & Andrea Morandi. (2022) Integrating radiation therapy with targeted treatments for breast cancer: From bench to bedside. Cancer Treatment Reviews 108, pages 102417.
Crossref
Hsin-Hua Lee, Chien-Hung Chen, Yu-Hsiang Huang, Cheng-Han Chiang & Ming-Yii Huang. (2022) Biomarkers of Favorable vs. Unfavorable Responses in Locally Advanced Rectal Cancer Patients Receiving Neoadjuvant Concurrent Chemoradiotherapy. Cells 11:10, pages 1611.
Crossref
Maximilian Fleischmann, Markus Diefenhardt, Emmanouil Fokas, Claus Rödel & Franz Rödel. (2021) Molekulare Prädiktoren des Tumoransprechens auf neoadjuvante Radiochemotherapie des RektumkarzinomsMolecular predictors of response to neoadjuvant chemoradiotherapy in rectal cancer. Der Onkologe 28:2, pages 118-125.
Crossref
Adile Orhan, Faisal Khesrawi, Michael Tvilling Madsen, Rasmus Peuliche Vogelsang, Niclas Dohrn, Anne-Marie Kanstrup Fiehn & Ismail Gögenur. (2022) Tumor-Infiltrating Lymphocytes as Biomarkers of Treatment Response and Long-Term Survival in Patients with Rectal Cancer: A Systematic Review and Meta-Analysis. Cancers 14:3, pages 636.
Crossref
Hugo Teixeira Farinha, Antonia Digklia, Dimitrios Schizas, Nicolas Demartines, Markus Schäfer & Styliani Mantziari. (2022) Immunotherapy for Esophageal Cancer: State-of-the Art in 2021. Cancers 14:3, pages 554.
Crossref
Aylin Alkan, Tobias Hofving, Eva Angenete & Ulf Yrlid. (2021) Biomarkers and cell-based models to predict the outcome of neoadjuvant therapy for rectal cancer patients. Biomarker Research 9:1.
Crossref
Bo Liang, Biao Zheng, Yan Zhou, Zheng-Quan Lai, Citing Zhang, Zilong Yan, Zhangfu Li, Xuefei Li, Peng Gong, Jianhua Qu & Jikui Liu. (2021) Characterization of a Tumor-Microenvironment-Relevant Gene Set Based on Tumor Severity in Colon Cancer and Evaluation of Its Potential for Dihydroartemisinin Targeting. Evidence-Based Complementary and Alternative Medicine 2021, pages 1-10.
Crossref
Anna Wilkins, Elisa Fontana, Gift Nyamundanda, Chanthirika Ragulan, Yatish Patil, David Mansfield, Jennifer Kingston, Fiona Errington-Mais, Daniel Bottomley, Katharina von Loga, Hannah Bye, Paul Carter, Emma Tinkler-Hundal, Arish Noshirwani, Jessica Downs, Magnus Dillon, Sandra Demaria, David Sebag-Montefiore, Kevin Harrington, Nick West, Alan Melcher & Anguraj Sadanandam. (2021) Differential and longitudinal immune gene patterns associated with reprogrammed microenvironment and viral mimicry in response to neoadjuvant radiotherapy in rectal cancer. Journal for ImmunoTherapy of Cancer 9:3, pages e001717.
Crossref
Thibaud Koessler & Francesco Sclafani. 2021.
Jihane Boustani, Valentin Derangère, Aurélie Bertaut, Olivier Adotevi, Véronique Morgand, Céline Charon-Barra, François Ghiringhelli & Céline Mirjolet. (2020) Radiotherapy Scheme Effect on PD-L1 Expression for Locally Advanced Rectal Cancer. Cells 9:9, pages 2071.
Crossref
Alberto Farolfi, Elisabetta Petracci, Luigi Serra, Alessandra Ravaioli, Sara Bravaccini, Sara Ravaioli, Maria Maddalena Tumedei, Paola Ulivi, Matteo Canale, Maurizio Puccetti, Fabio Falcini, Secondo Folli, Annalisa Curcio & Andrea Rocca. (2020) Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinoma in situ. Frontiers in Oncology 10.
Crossref
Tom van den Ende, Héctor G. van den Boorn, Nadine M. Hoonhout, Faridi S. van Etten-Jamaludin, Sybren L. Meijer, Sarah Derks, Tanja D. de Gruijl, Maarten F. Bijlsma, Martijn G.H. van Oijen & Hanneke W.M. van Laarhoven. (2020) Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1874:1, pages 188386.
Crossref
Gang Chen, Lin Wang, Tongwei Diao, Ying Chen, Chengbo Cao & Xindong Zhang. (2020) Analysis of immune‑related signatures of colorectal cancer identifying two different immune phenotypes: Evidence for immune checkpoint inhibitor therapy. Oncology Letters.
Crossref
Holger H. Göbel, Maike J. Büttner-Herold, Nicole Fuhrich, Thomas Aigner, Gerhard G. Grabenbauer & Luitpold V.R. Distel. (2020) Cytotoxic and immunosuppressive inflammatory cells predict regression and prognosis following neoadjuvant radiochemotherapy of oesophageal adenocarcinoma. Radiotherapy and Oncology 146, pages 151-160.
Crossref
L.M. Abbassi, K.I. Cao & Y.M. Kirova. (2020) Immunothérapie et radiothérapie dans la prise en charge du cancer du sein : rationnel et synthèse de la littérature sur les applications cliniques actuelles. Cancer/Radiothérapie 24:1, pages 73-80.
Crossref
James H Park, Hester Wyk, Donald C McMillan, Joanne Edwards, Clare Orange, Paul G Horgan & Campbell SD Roxburgh. (2019) Preoperative, biopsy‐based assessment of the tumour microenvironment in patients with primary operable colorectal cancer. The Journal of Pathology: Clinical Research 6:1, pages 30-39.
Crossref
Mathieu Grapin, Corentin Richard, Emeric Limagne, Romain Boidot, Véronique Morgand, Aurélie Bertaut, Valentin Derangere, Pierre-Antoine Laurent, Marion Thibaudin, Jean David Fumet, Gilles Crehange, François Ghiringhelli & Céline Mirjolet. (2019) Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination. Journal for ImmunoTherapy of Cancer 7:1.
Crossref
Yongfu Xiong, Kang Wang, He Zhou, Linglong Peng, Wenxian You & Zhongxue Fu. (2018) Profiles of immune infiltration in colorectal cancer and their clinical significant: A gene expression‐based study. Cancer Medicine 7:9, pages 4496-4508.
Crossref
Caroline Verbeke, Lena Häberle, Daniela Lenggenhager & Irene Esposito. (2018) Pathology assessment of pancreatic cancer following neoadjuvant treatment: Time to move on. Pancreatology 18:5, pages 467-476.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.